A phase II trial of sequential MTx and 5-FU alternated with 4-epidoxorubicin and cisplatin in advanced gastric cancer.
Twenty-one patients with advanced gastric adenocarcinoma were treated with a combination chemotherapy schedule of sequential methotrexate and 5-fluorouracil alternated with 4-epidoxorubicin and cisplatin. This scheme was active, with 7 partial responses leading to a response rate of 33% (+/- 20%). In two cases the tumor became operable. No severe toxicity developed and the treatment was usually well tolerated.
Taal
B G
BG
Department of Gastroenterology, The Netherland Cancer Institute, Amsterdam.
ten Bokkel Huinink
W W
WW
Simonetti
G
G
Franklin
H
H
McVie
J G
JG
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
D015251:Epirubicin; D004317:Doxorubicin; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate